Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03242824 · ClinicalTrials.gov registry record · Phase 2
The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT03242824: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT03242824 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 21 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03242824, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
This proposal is for a pilot study comparing volumes of 18F-DOPA-PET avidity with contrast enhancement and T2 FLAIR on MRI. Investigators then plan to compare patterns of failure with target volumes, pre-treatment MRI changes and pre-treatment 18F-DOPA-PET.
Primary Outcome
measured by reviewing 18F-DOPA-PET and conventional MRI with historical controls
Interventions
- PROCEDURE Positron Emission Tomography
- RADIATION Intensity-Modulated Radiation Therapy
- DRUG Fluorine F 18 Fluorodopa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-09-29 |
| Est. Completion | 2021-06-16 |
| Phase | Phase 2 |
What the finished NCT03242824 record still lists
NCT03242824 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 3 interventions - of which Positron Emission Tomography is the first listed.
NCT03242824 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03242824 about?
NCT03242824 is a clinical study titled "The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma". This proposal is for a pilot study comparing volumes of 18F-DOPA-PET avidity with contrast enhancement and T2 FLAIR on MRI. Investigators then plan to compare patterns of failure with target volumes, pre-treatment MRI changes and pre-treatment 18F-DOPA-PET.
What is the current status of trial NCT03242824?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2017-09-29. Estimated completion is 2021-06-16.
What interventions are being tested in trial NCT03242824?
The interventions under investigation include: Positron Emission Tomography (PROCEDURE), Intensity-Modulated Radiation Therapy (RADIATION), Fluorine F 18 Fluorodopa (DRUG).
Who is sponsoring clinical trial NCT03242824?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03242824's enrollment target sits among peer trials
21 1794th of 2000 higher than 196 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI